WallStreetZenWallStreetZen

NASDAQ: ALNY
Alnylam Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Alnylam Pharmaceuticals revenue was $2.25B for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $593.2M, up 18.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ALNY annual revenue was $2.2B, with 23% growth year-over-year.

ALNY past revenue growth

How has ALNY's revenue growth performed historically?

Company
22.97%
Industry
443.32%
Market
20.2%
ALNY's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ALNY's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ALNY's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ALNY revenue history

Current Revenue
$2.2B
Current Earnings
-$278.2M
Current Profit Margin
-12.4%

Be the first to know when ALNY announces revenue.

ALNY Revenue History By Year

ALNY Yearly RevenueALNY RevenueALNY ChangeALNY Revenue Growth
2024-12-31$2.25B$419.95M+22.97%
2023-12-31$1.83B$790.87M+76.23%
2022-12-31$1.04B$193.13M+22.88%
2021-12-31$844.29M$351.43M+71.31%
2020-12-31$492.85M$273.10M+124.28%
2019-12-31$219.75M$144.84M+193.36%
2018-12-31$74.91M-$15.00M-16.69%
2017-12-31$89.91M$42.75M+90.66%
2016-12-31$47.16M$6.06M+14.75%
2015-12-31$41.10M-$9.46M-18.72%
2014-12-31$50.56M$3.39M+7.20%
2013-12-31$47.17M-$19.56M-29.31%
2012-12-31$66.73M-$16.03M-19.37%
2011-12-31$82.76M-$17.28M-17.28%
2010-12-31$100.04M-$492.00k-0.49%
2009-12-31$100.53M$4.37M+4.54%
2008-12-31$96.16M$45.27M+88.94%
2007-12-31$50.90M$23.97M+89.00%
2006-12-31$26.93M$21.21M+371.13%
2005-12-31$5.72M$1.44M+33.61%
2004-12-31$4.28M$4.10M+2,330.68%
2003-12-31$176.00kN/AN/A

1 of 2

Alnylam Pharmaceuticals Revenue FAQ

What was ALNY's revenue last quarter?

On Invalid Date, Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q4 2024 revenue of $593.17 million up 34.9% year over year. In the same quarter last year, Alnylam Pharmaceuticals's revenue was $439.72 million.

What was Alnylam Pharmaceuticals's revenue in 2024?

Alnylam Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $2.25 billion, a 22.97% increase year over year.

How much does Alnylam Pharmaceuticals make in a day?

Based on Alnylam Pharmaceuticals annual revenue for the past five years, ALNY makes an average of $3,534,845.48 per day.

What was Alnylam Pharmaceuticals's annual revenue growth in the past year?

As of Q2 2025, Alnylam Pharmaceuticals's revenue has grown 22.97% year over year. This is 420.35 percentage points lower than the US Biotechnology industry revenue growth rate of 443.32%. Alnylam Pharmaceuticals's revenue in the past year totaled $2.25 billion.

How much does Alnylam Pharmaceuticals make in a year?

Alnylam Pharmaceuticals's revenue by year for the past five years is:
  • Alnylam Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $2.25 billion, a 22.97% increase year over year.
  • Alnylam Pharmaceuticals's annual revenue for Dec 31, 2023 was $1.83 billion, a 76.23% increase from 2022.
  • Alnylam Pharmaceuticals's annual revenue for 2022 was $1.04 billion, a 22.88% increase from 2021.
  • Alnylam Pharmaceuticals's annual revenue for 2021 was $844.29 million, a 71.31% increase from 2020.
  • Alnylam Pharmaceuticals's annual revenue for 2020 was $492.85 million, a 124.28% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.